Jonas A Nilsson

List of Publications by Year
in descending order

76 papers	8,073 citations	81900 39 h-index	66911 78 g-index
84 all docs	84 docs citations	84 times ranked	15500 citing authors

#	Article	IF	Citations
1	Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors. ACS Nano, 2013, 7, 7698-7710.	14.6	768
2	Antioxidants Accelerate Lung Cancer Progression in Mice. Science Translational Medicine, 2014, 6, 221ra15.	12.4	663
3	DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity. Immunity, 2015, 42, 332-343.	14.3	567
4	Antioxidants can increase melanoma metastasis in mice. Science Translational Medicine, 2015, 7, 308re8.	12.4	468
5	Myc pathways provoking cell suicide and cancer. Oncogene, 2003, 22, 9007-9021.	5.9	420
6	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 2005, 436, 807-811.	27.8	419
7	MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature, 2014, 508, 215-221.	27.8	419
8	c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes and Development, 2002, 16, 2530-2543.	5.9	409
9	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics, 2014, 46, 1258-1263.	21.4	269
10	BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2721-30.	7.1	204
11	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood, 2010, 116, 1498-1505.	1.4	196
12	RNAi delivery by exosome-mimetic nanovesicles â€" Implications for targeting c-Myc in cancer. Biomaterials, 2016, 102, 231-238.	11.4	188
13	Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell, 2005, 7, 433-444.	16.8	179
14	Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells â€" Evidence of unique microRNA cargos. RNA Biology, 2015, 12, 810-823.	3.1	164
15	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 2017, 23, 929-937.	30.7	146
16	Selection against <i>PUMA</i> Gene Expression in Myc-Driven B-Cell Lymphomagenesis. Molecular and Cellular Biology, 2008, 28, 5391-5402.	2.3	130
17	Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells. Clinical Cancer Research, 2011, 17, 7067-7079.	7.0	124
18	c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL. Molecular and Cellular Biology, 2003, 23, 7256-7270.	2.3	123

#	Article	IF	Citations
19	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature Communications, 2017, 8, 707.	12.8	123
20	Endosomal signalling via exosome surface TGFÎ²â€1. Journal of Extracellular Vesicles, 2019, 8, 1650458.	12.2	112
21	Molecular profiling of driver events in metastatic uveal melanoma. Nature Communications, 2020, 11, 1894.	12.8	108
22	Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia. Brain, 2017, 140, 353-369.	7.6	106
23	BRAF ^{V600} inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5930-E5939.	7.1	101
24	Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO Journal, 2007, 26, 2562-2574.	7.8	88
25	Mnt Loss Triggers Myc Transcription Targets, Proliferation, Apoptosis, and Transformation. Molecular and Cellular Biology, 2004, 24, 1560-1569.	2.3	85
26	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nature Communications, 2021, 12, 5155.	12.8	85
27	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapyâ€“Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Research, 2019, 79, 899-904.	0.9	84
28	Mouse Genetics Suggests Cell-Context Dependency for Myc-Regulated Metabolic Enzymes during Tumorigenesis. PLoS Genetics, 2012, 8, e1002573.	3.5	75
29	Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood, 2014, 124, 2081-2090.	1.4	72
30	Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes. Immunity, 2015, 43, 647-659.	14.3	72
31	Antizyme inhibitor is rapidly induced in growth-stimulated mouse fibroblasts and releases ornithine decarboxylase from antizyme suppression. Biochemical Journal, 2000, 346, 699-704.	3.7	65
32	Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget, 2014, 5, 9609-9618.	1.8	62
33	The Novel ETS Factor TEL2 Cooperates with Myc in B Lymphomagenesis. Molecular and Cellular Biology, 2005, 25, 2395-2405.	2.3	61
34	SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut, 2020, 69, 1472-1482.	12.1	61
35	Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13768-13773.	7.1	50
36	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer, 2019, 19, 415.	2.6	49

#	Article	IF	Citations
37	The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget, 2011, 2, 448-460.	1.8	45
38	Chemoprevention of B-Cell Lymphomas by Inhibition of the Myc Target Spermidine Synthase. Cancer Prevention Research, 2010, 3, 140-147.	1.5	42
39	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
40	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death and Disease, 2018, 9, 810.	6.3	38
41	Polyamines Regulate Both Transcription and Translation of the Gene Encoding Ornithine Decarboxylase Antizyme in Mouse. FEBS Journal, 1997, 250, 223-231.	0.2	36
42	Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. British Journal of Pharmacology, 2001, 133, 513-520.	5.4	36
43	Nfkb1 is dispensable for Myc-induced lymphomagenesis. Oncogene, 2005, 24, 6231-6240.	5.9	36
44	Pathogenesis and therapeutic targeting of aberrant <scp>MYC</scp> expression in haematological cancers. British Journal of Haematology, 2017, 179, 724-738.	2.5	36
45	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials, 2014, 15, 317.	1.6	33
46	Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood, 2009, 113, 4281-4288.	1.4	31
47	Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle, 2011, 10, 3598-3607.	2.6	31
48	Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. Journal of Neurochemistry, 2006, 99, 677-688.	3.9	27
49	Skp2 Directs Myc-Mediated Suppression of p27Kip1 yet Has Modest Effects on Myc-Driven Lymphomagenesis. Molecular Cancer Research, 2010, 8, 353-362.	3.4	26
50	Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Annals of Oncology, 2020, 31, 266-273.	1.2	26
51	Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. Frontiers in Oncology, 2018, 8, 218.	2.8	25
52	Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Annals of Surgical Oncology, 2016, 23, 1327-1334.	1.5	24
53	Skin fibroblasts from spermine synthase-deficient hemizygous gyro male (Gy/Y) mice overproduce spermidine and exhibit increased resistance to oxidative stress but decreased resistance to UV irradiation. Biochemical Journal, 2000, 352, 381-387.	3.7	24
54	Id2 Is Dispensable for Myc-Induced Lymphomagenesis. Cancer Research, 2004, 64, 7296-7301.	0.9	18

#	Article	IF	Citations
55	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death and Disease, 2017, 8, e2982-e2982.	6.3	17
56	Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Research, 2016, 76, 2376-2383.	0.9	15
57	Cks1 Is Required for Tumor Cell Proliferation but Not Sufficient to Induce Hematopoietic Malignancies. PLoS ONE, 2012, 7, e37433.	2.5	14
58	Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma. American Journal of Pathology, 2021, 191, 2023-2038.	3.8	13
59	Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. Oncotarget, 2016, 7, 23801-23811.	1.8	13
60	Mnt: Master Regulator of the Max Network. Cell Cycle, 2004, 3, 586-588.	2.6	11
61	Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. JCO Precision Oncology, 2018, 2, 1-25.	3.0	10
62	Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma. Annals of Surgical Oncology, 2019, 26, 1055-1062.	1.5	10
63	The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanomaâ€"A Nation-Wide Swedish Population-Based Retrospective Register Study. Cancers, 2020, 12, 3228.	3.7	9
64	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. Melanoma Research, 2022, 32, 241-248.	1.2	9
65	Discovery of a rare <i>GKAP1-NTRK2</i> fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib. Cancer Biology and Therapy, 2021, 22, 184-195.	3.4	7
66	The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion. Cancers, 2021, 13, 4305.	3.7	7
67	Reduced <i>FAS</i> transcription in clones of U937 cells that have acquired resistance to Fasâ€induced apoptosis. FEBS Journal, 2009, 276, 497-508.	4.7	5
68	Mnt: master regulator of the Max network. Cell Cycle, 2004, 3, 588-90.	2.6	5
69	H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines. Nature Genetics, 2019, 51, 1426-1427.	21.4	4
70	Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells. Life Science Alliance, 2020, 3, e202000671.	2.8	4
71	Clinical, genetic and experimental studies of the Brookeâ€"Spiegler (CYLD) skin tumor syndrome. Journal of Plastic Surgery and Hand Surgery, 2019, 53, 71-75.	0.8	3
72	BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma. Epigenetics, 2021, 16, 54-63.	2.7	3

#	Article	IF	Citations
73	A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells. Cancers, 2022, 14, 2882.	3.7	3
74	Inhibition of cellular FLICE-like inhibitory protein abolishes insensitivity to interferon-Î± and death receptor stimulation in resistant variants of the human U937 cell line. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 783-794.	4.9	2
75	BRAF status as a predictive factor for response in isolated limb perfusion. International Journal of Hyperthermia, 2019, 36, 510-514.	2.5	2
76	Reply to Comment on Katsarelias, D., et al. â€œThe Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanomaâ€"A Nation-Wide Swedish Population-Based Retrospective Register Study.â€• Cancers 2020, 12, 3228. Cancers, 2021, 13, 92.	3.7	1